Psoralidin, a prenylated coumestan, as a novel anti-osteoporosis candidate to enhance bone formation of osteoblasts and decrease bone resorption of osteoclasts

Zhai, Yuankun; Li, Yingying; Wang, Yanping; Cui, Jiawei; Feng, Kun; Kong, Xiangkun; Chen, Li

doi:10.1016/j.ejphar.2017.03.001

Cited by 47 publications

(19 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The similar structure of PSO with coumestrol, a phytoestrogen, allows PSO to bind efficiently to estrogen receptors. In vivo studies performed in ovariectomized rats showed that PSO could inhibit bone resorption of osteoclasts and stimulate the bone formation (Zhai et al, 2017).…”

Section: In Vivo Studiesmentioning

confidence: 99%

Pharmacological Activities of Psoralidin: A Comprehensive Review of the Molecular Mechanisms of Action

et al. 2020

View full text Add to dashboard Cite

Analysis of the most relevant studies on the pharmacological properties and molecular mechanisms of psoralidin, a bioactive compound from the seeds of Cullen corylifolium (L.) Medik. confirmed its complex therapeutic potential. In the last years, the interest of the scientific community regarding psoralidin increased, especially after the discovery of its benefits in estrogen-related diseases and as a chemopreventive agent. Growing preclinical pieces of evidence indicate that psoralidin has anticancer, antiosteoporotic, anti-inflammatory, anti-vitiligo, antibacterial, antiviral, and antidepressant-like effects. Here, we provide a comprehensive and critical review of psoralidin on its bioavailability, pharmacological activities with focus on molecular mechanisms and cell signaling pathways. In this review, we conducted literature research on the PubMed database using the following keywords: "Psoralidin" or "therapeutic effects" or "biological activity" or "Cullen corylifolium" in order to identify relevant studies regarding PSO bioavailability and mechanisms of therapeutic effects in different diseases based on preclinical, experimental studies. In the light of psoralidin beneficial actions for human health, this paper gathers complete information on its pharmacotherapeutic effects and opens new natural therapeutic perspectives in chronic diseases.

show abstract

Section: In Vivo Studiesmentioning

confidence: 99%

Pharmacological Activities of Psoralidin: A Comprehensive Review of the Molecular Mechanisms of Action

et al. 2020

View full text Add to dashboard Cite

show abstract

“…To reduce the rate of osteoporosis-related fractures in women, current therapeutics principally focus on increasing bone formation or decreasing bone resorption (5). A number of medicines also aim to restore bone loss by inducing osteoblasts to form new bone tissue (6).…”

Section: Introductionmentioning

confidence: 99%

Psoralen stimulates osteoblast proliferation through the activation of nuclear factor-κB-mitogen-activated protein kinase signaling

Feimeng

Huang³

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Osteoporosis is a systemic skeletal disease that leads to increased bone fragility and susceptibility to fracture. Approximately 50% of postmenopausal women develop osteoporosis as a result of postmenopausal estrogen deficiency. To reduce fractures related to osteoporosis in women, previous studies have focused on therapeutic strategies that aim to increase bone formation or decrease bone resorption. However, pharmacological agents that aim to improve bone fracture susceptibility exhibit side effects. Current studies are investigating natural alternatives that possess the benefits of selective estrogen receptor modulators (SERMs) without the adverse effects. Recent studies have indicated that phytoestrogen may be an ideal natural SERM for the treatment of osteoporosis. In Chinese herbal medicine, psoralen, as the predominant substance of Psoralea corylifolia, is considered to be a phytoestrogen and is used as a remedy for osteoporosis. A number of studies have demonstrated the efficacy of psoralen in bone formation. However, the pathways and underlying molecular mechanisms that participate in psoralen-induced osteoblast formation are not well understood. In the present study, hFOB1.19 cells were treated with psoralen at different concentrations (0, 5, 10, 15 and 20 µM) for 0, 24, 36, 48 and 72 h, respectively. Reverse transcription-quantitative polymerase chain reaction and western blot assays were performed to detect glucose transporter 3 (GLUT3) expression. A cell counting kit-8 assay was used to analyze cell proliferation. In addition the effects of mitogen activated protein kinase inhibitors on extracellular signal-regulated kinase (ERK), phosphorylated (p)-ERK, p38, p-p38, c-Jun N-terminal kinase (JNK) and p-JNK expressions and cell proliferation were measured, as was the effect of nuclear factor (NF)-κB inhibitor on P65 and GLUT3 expressions and cell proliferation. The results indicated that psoralen stimulates hFOB1.19 cell proliferation in a dose-dependent manner (P<0.05). Phospho-ERK, p38 and JNK were markedly increased by psoralen compared with the control group (P<0.05), and the specific inhibitors of ERK (SCH772984), p38 (SB203580) and JNK (SP600125) reversed the stimulatory effects of psoralen on signal marker phosphorylation (P<0.05). The rate of psoralen-induced cell proliferation was significantly suppressed by inhibitors of ERK, JNK and p38 compared with psoralen treatment alone (P<0.05). In addition, psoralen stimulated osteoblast proliferation via the NF-κB signaling pathway. Therefore, the present findings suggest that psoralen may be a potential natural alternative to SERMs in the treatment of osteoporosis and fractures.

show abstract

“…Genistein is an isoflavone exhibiting estrogenic effect on bone. It modulates B-lymphopoiesis in bone marrow and inhibits bone degradation without any estrogenic effect in the uterus [ 27 , 41 ]. The antiosteoporotic effects of flavonoids depend on the mixture of their estrogenic agonist–antagonist properties [ 27 , 41 ].…”

Section: Antiosteoporotic Constituents Extracted From Natural Planmentioning

confidence: 99%

“…It modulates B-lymphopoiesis in bone marrow and inhibits bone degradation without any estrogenic effect in the uterus [ 27 , 41 ]. The antiosteoporotic effects of flavonoids depend on the mixture of their estrogenic agonist–antagonist properties [ 27 , 41 ]. Other studies suggest that the antiosteoporotic effects may be derived from other biochemical properties of flavonoids, including enzymatic inhibition of certain protein kinases or activation of estrogen type I receptors [ 27 ].…”

Section: Antiosteoporotic Constituents Extracted From Natural Planmentioning

confidence: 99%

Protective Effects of Selected Botanical Agents on Bone

Jolly

Chin

Alias

et al. 2018

IJERPH

View full text Add to dashboard Cite

Osteoporosis is a serious health problem affecting more than 200 million elderly people worldwide. The early symptoms of this disease are hardly detectable. It causes progressive bone loss, which ultimately renders the patients susceptible to fractures. Osteoporosis must be prevented because the associated fragility fractures result in high morbidity, mortality, and healthcare costs. Many plants used in herbal medicine contain bioactive compounds possessing skeletal protective effects. This paper explores the anti-osteoporotic properties of selected herbal plants, including their actions on osteoblasts (bone forming cells), osteoclasts (bone resorbing cells), and bone remodelling. Some of the herbal plant families included in this review are Berberidaceae, Fabaceae, Arecaceae, Labiatae, Simaroubaceaea, and Myrsinaceae. Their active constituents, mechanisms of action, and pharmaceutical applications were discussed. The literature shows that very few herbal plants have undergone human clinical trials to evaluate their pharmacological effects on bone to date. Therefore, more intensive research should be performed on these plants to validate their anti-osteoporotic properties so that they can complement the currently available conventional drugs in the battle against osteoporosis.

show abstract

Psoralidin, a prenylated coumestan, as a novel anti-osteoporosis candidate to enhance bone formation of osteoblasts and decrease bone resorption of osteoclasts

Cited by 47 publications

References 25 publications

Pharmacological Activities of Psoralidin: A Comprehensive Review of the Molecular Mechanisms of Action

Pharmacological Activities of Psoralidin: A Comprehensive Review of the Molecular Mechanisms of Action

Psoralen stimulates osteoblast proliferation through the activation of nuclear factor-κB-mitogen-activated protein kinase signaling

Protective Effects of Selected Botanical Agents on Bone

Contact Info

Product

Resources

About